Agewell Brief

A sleep EEG 'brain age' score tracked future dementia risk

Sun, 02 Aug 2026 10:32:43 GMT

Illustrative photo by RDNE Stock project on Pexels

A machine-learning model estimated “brain age” from overnight sleep recordings. Across five long-running cohorts, each additional 10 years between estimated brain age and chronological age was associated with a 39% higher risk of dementia.

Why This Matters

Dementia risk does not reveal itself through one measurement. That makes researchers interested in signals that can add useful information before symptoms appear. This study examined one such candidate: the fine-grained electrical patterns recorded by an electroencephalogram, or EEG, during sleep.

The idea is strikingly simple. A model compares patterns in a person’s sleeping brain with patterns expected at their chronological age. The difference becomes a “brain age index.” A positive score means the EEG looks older than expected; a negative score means it looks younger. The question was whether that gap tracked who later developed dementia.

What the Study Found

Researchers pooled individual data from 7,105 adults in five community-based longitudinal studies. Participants had no dementia when their overnight sleep recordings were collected. Follow-up varied by cohort, with median times to dementia ranging from 3.6 to 16.9 years.

The model combined 13 EEG features, including patterns related to brain-wave power, sleep spindles, and the shape of signals during different sleep stages. During follow-up, 1,088 participants developed dementia or probable dementia under the definitions used by their respective cohorts.

For every 10-year increase in the brain age index, the adjusted risk of incident dementia was 39% higher. The association remained after accounting for age, sex, education, body mass index, smoking, sleep medication, physical activity, and other factors. It became smaller—but remained statistically significant—when the researchers added medical conditions, sleep-apnea measurements, and available genetic-risk data.

That distinction matters. Broad measures such as time spent in a sleep stage have produced inconsistent results in earlier pooled analyses. This model was built to combine subtler EEG features into one interpretable score.

How to Interpret This

This was an individual-participant meta-analysis of observational cohorts. It found an association; it did not show that an older EEG-derived brain age causes dementia. Nor did it test whether changing sleep habits can alter the score or prevent disease.

There are practical limits, too. Dementia was identified differently across the five cohorts. The cohorts also differed substantially: one consisted entirely of men and another entirely of women. Although the pooled sample included several racial and ethnic groups, representation was uneven across studies.

Most importantly, “brain age” is not a diagnosis. The paper describes a research marker calculated from overnight polysomnography—not a consumer score people can currently look up, and not a clinical test that can predict an individual’s future with certainty. The authors conclude that its predictive value still needs evaluation.

Practical Next Steps

For now, this result is useful as a view of where dementia-risk research is heading. It shows that information already present in an overnight sleep study may contain more detail than standard sleep summaries reveal.

It does not create a new action item for otherwise healthy readers. There is no validated brain-age target to chase, home device to buy, or regimen shown by this study to make the score younger.

If changes in memory, thinking, or sleep are interfering with daily life, those concerns are worth discussing with a qualified clinician. That advice does not depend on this model. The next meaningful step for the research is prospective validation: testing whether the score improves real clinical decisions beyond information doctors already have.

Three things to remember

The analysis combined sleep EEG data from 7,105 adults across five cohorts.
Each 10-year higher brain-age gap tracked a 39% higher dementia risk.
The score remains a research marker—not a diagnosis or consumer test.

Source

This analysis is based on AI can tell if your brain is aging faster than you are from ScienceDaily Healthy Aging. Read the original report for full context.

Primary study: JAMA Network Open — Machine Learning–Based Sleep Electroencephalographic Brain Age Index and Dementia Risk.

Health note: This observational analysis cannot establish causation or predict an individual’s future. The score is not ready for routine clinical use.

Mediterranean eating pattern linked to two mitochondrial microproteins

Sun, 02 Aug 2026 10:32:43 GMT

Illustrative photo by Mikhail Nilov on Pexels

A 49-person pilot study found higher levels of two mitochondrial microproteins among older adults who reported closer adherence to a Mediterranean eating pattern.

Three things to remember

The cross-sectional study involved 49 patients with atrial fibrillation.
Higher adherence tracked higher Humanin and SHMOOSE blood levels.
The study cannot show that the diet caused those biological differences.

Source

This signal is based on Mediterranean diet may activate tiny proteins that protect the heart and brain from ScienceDaily Healthy Aging. Read the original report for full context.

Primary study: Frontiers in Nutrition — Mediterranean diet adherence and mitochondrial microproteins.

Health note: This was a small, cross-sectional convenience sample. It identifies associations and does not test whether changing diet raises these proteins or prevents disease.

FDA warns of hidden ingredients in some sleep, skin, and bodybuilding products

Sun, 02 Aug 2026 10:32:43 GMT

Illustrative photo by Edward Jenner on Pexels

Products marketed as “all natural,” foods, or dietary supplements can still contain undeclared drug ingredients. The FDA maintains a searchable notification list for checking specific products.

Three things to remember

Some products in these categories have contained dangerous hidden ingredients.
Labels such as “all natural” or “dietary supplement” do not guarantee safety.
Search the FDA database for a specific product before buying or using it.

Source

This signal is based on Sleep, Skin, Bodybuilding and Other Product Notifications from FDA Tainted Supplements. Read the original report for full context.

Health note: The warning does not apply to every product in these categories. Use the FDA’s notifications to check a specific name and follow any listed safety instructions.

New Blood Test May Predict Alzheimer's Symptoms Years Ahead

Sun, 02 Aug 2026 09:07:46 GMT

Illustrative photo by https://kaboompics.com/ on Pexels

A new biomarker model could sharpen forecasts of disease progression years before symptoms begin.

Why This Matters

For people living with Alzheimer's disease and their families, one of the hardest questions is: "How fast will this progress?" Current biomarkers can identify Alzheimer's-related changes well before symptoms appear, but predicting when memory and thinking problems will begin remains difficult.

Now, researchers funded by the National Institutes of Health have identified a new type of biomarker in the blood that may change that. Small loops of genetic material called circular RNAs (circRNAs) appear to be more dynamic than amyloid plaques, reflecting recent brain activity. Elevated levels of certain circRNAs nearly tripled a person's risk of developing Alzheimer's symptoms, suggesting they could serve as an early warning system.

The possible value reaches beyond forecasting. Identifying people who are close to developing symptoms could help researchers choose the right participants for clinical trials and judge more clearly whether a treatment delays cognitive decline.

What the Study Found

The research, published in Nature Medicine, analyzed blood data from more than 1,200 people across multiple independent cohorts. The team, led by Dr. Carlos Cruchaga at Washington University School of Medicine in St. Louis, identified a set of 34 circRNAs associated with Alzheimer's disease. They then built predictive models based on these circRNAs and compared them to models based on pTau217, the leading clinical blood biomarker for Alzheimer's.

When identifying Alzheimer's pathology, the circRNA model performed comparably to—and in the discovery data better than—the pTau217 model. It also outperformed pTau217 at predicting progression to symptomatic Alzheimer's. The levels of these circRNAs appeared to diverge from normal roughly two to four years before symptom onset. The findings were then tested in two independent cohorts.

These results suggest that circRNAs may provide a more complete picture of the disease's trajectory. As Dr. Cruchaga notes, patients treated with amyloid-removing therapies can become pTau negative but still have Alzheimer's. Circular RNAs might offer a broader view of the disease biology, potentially helping monitor treatment response.

How to Interpret the Findings

This is early research, not a test people can request today. The study found an association between circRNA levels and Alzheimer's progression; it did not show that circRNAs cause the disease. Larger prospective studies must now test how reliably the model performs when used to forecast future patients.

The study's strength lies in its use of multiple independent cohorts and its comparison to an established biomarker. However, the predictive models were developed and tested in specific groups, and their real-world performance may vary. The authors themselves are working with commercial partners to develop clinical assays, indicating that translation to practice will take time.

For now, the result is a meaningful advance in forecasting research. If it holds up, circRNAs could help doctors and families understand the likely timing of symptom onset. It does not yet change current diagnostic or treatment recommendations.

Practical Next Steps

The practical takeaway is clarity about what this study can—and cannot—do. The research points toward a future forecasting tool, while the authors work with commercial partners on clinical assays. It does not replace a medical evaluation, and no consumer version of the test is currently available.

Anyone noticing persistent changes in memory or thinking can bring a written list of examples, medications, and questions to a medical appointment. That conversation uses tools available now; the circRNA model belongs to the next stage of Alzheimer's research.

Three things to remember

Circular RNAs in blood may predict Alzheimer's symptom onset.
They outperform pTau217 in forecasting disease progression.
Test not yet available; more research needed.

Source

This analysis is based on New Alzheimer’s blood test may tell when symptoms are around the corner from NIH News Releases. Read the original report for full context.

Health note: The biomarker model is not a clinical test and still needs prospective validation in larger cohorts.

A potential sleep crisis among workers over 50: Study links work-related stress to range of well-being issues

Sun, 02 Aug 2026 09:07:46 GMT

Illustrative photo by SHVETS production on Pexels

A new study finds that work-related stress is associated with significant sleep disturbances in people over 50, with many experiencing persistent issues.

Three things to remember

Nearly 70% of participants had persistent, clinically significant sleep problems.
Almost 92% met the threshold for a sleep disorder at least once.
Work-related stress is linked to a range of well-being issues.

Source

This signal is based on A potential sleep crisis among workers over 50: Study links work-related stress to range of well-being issues from Medical Xpress Healthy Aging. Read the original report for full context.

Health note: The study followed 45 workers aged 50–66. It found associations; it did not prove that workplace stress caused the sleep problems.

A new plan for healthy aging starts before we're born

Sun, 02 Aug 2026 09:07:46 GMT

Illustrative photo by Askar Abayev on Pexels

Scientists are developing a new field to help us stay healthier longer, with roots in early life.

Three things to remember

Lifespans are increasing in many countries, but healthspan may lag.
Longevity medicine aims to extend healthy years, not just life.
New approaches may start before we're born, shaping future health.

Source

This signal is based on A new plan for healthy aging starts before we're born from Medical Xpress. Read the original report for full context.

Health note: This is a proposal for new research infrastructure, not evidence for a specific intervention.